Literature DB >> 22988132

The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity.

Oliver Seifert1, Aline Plappert, Nadine Heidel, Sina Fellermeier, Sylvia K E Messerschmidt, Fabian Richter, Roland E Kontermann.   

Abstract

Dimeric assembly of antibody fragments and other therapeutic molecules can result in increased binding and improved bioactivity. Here, we investigated the use of the IgM heavy chain domain 2 (MHD2) as covalently linked homodimerization module. Fusion of single-chain fragment variable (scFv) molecules directed against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 to the N- and/or C-terminus of the MHD2, respectively, resulted in molecules with single or dual specificity for tumor cells. Bispecific tetravalent molecules were further generated by fusing a bispecific single-chain diabody directed against EGFR and epithelial cell adhesion molecule to the N-terminus of the MHD2. By combining an anti-EGFR scFv with a single-chain derivative of tumor necrosis factor, a tetravalent bifunctional fusion protein was produced. This fusion protein exhibited improved TNF activity, also mimicking the membrane-bound form of TNF, as shown by the activation of TNFR2-mediated cell killing. Furthermore, the scFv moiety allowed for an antigen-dependent delivery of TNF to EGFR-positive cells and an improved stimulatory TNF action on these cells. Thus, we established the MHD2 as a versatile module for the generation of bispecific and bifunctional fusion proteins.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22988132     DOI: 10.1093/protein/gzs059

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  4 in total

1.  Cryomicroscopy reveals the structural basis for a flexible hinge motion in the immunoglobulin M pentamer.

Authors:  Qu Chen; Rajesh Menon; Lesley J Calder; Pavel Tolar; Peter B Rosenthal
Journal:  Nat Commun       Date:  2022-10-23       Impact factor: 17.694

Review 2.  The making of bispecific antibodies.

Authors:  Ulrich Brinkmann; Roland E Kontermann
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

3.  The eIg technology to generate Ig-like bispecific antibodies.

Authors:  Lennart Kühl; Nadine Aschmoneit; Roland E Kontermann; Oliver Seifert
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

4.  Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells.

Authors:  Meike Hutt; Sina Fellermeier-Kopf; Oliver Seifert; Lisa C Schmitt; Klaus Pfizenmaier; Roland E Kontermann
Journal:  Oncotarget       Date:  2018-01-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.